Company Filing History:
Years Active: 2015-2025
Title: Satoshi Yamamura: Innovator in Antibody Research
Introduction
Satoshi Yamamura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of humanized antibodies. With a total of 3 patents to his name, Yamamura's work focuses on enhancing muscle mass through innovative therapeutic approaches.
Latest Patents
Yamamura's latest patents include an anti-IGF-I receptor humanized antibody. This invention provides a humanized antibody that increases muscle mass without lowering blood glucose levels. The antibody is characterized by a specific amino acid sequence, such as SEQ ID NOs: 1 to 6, which serves as a CDR sequence and specifically binds to the IGF-I receptor's extracellular domain. Another notable patent involves anti-IGF-I receptor antibodies, which bind specifically to the IGF-I receptor of vertebrates and promote the proliferation of vertebrate-derived cells.
Career Highlights
Satoshi Yamamura is currently associated with Teijin Pharma Limited, where he continues to advance his research in antibody development. His work has the potential to impact various therapeutic applications, particularly in muscle-related conditions.
Collaborations
Yamamura collaborates with esteemed colleagues, including Akira Tanokura and Hirotsugu Kato, to further enhance the scope and impact of his research.
Conclusion
Satoshi Yamamura's innovative work in the field of humanized antibodies positions him as a key figure in biotechnology. His contributions are paving the way for new therapeutic solutions that could significantly benefit patients.